Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.
<h4>Background</h4>Giving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion surgery of thoracic and lumb...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0237566 |
_version_ | 1818725904077029376 |
---|---|
author | Shih-Hao Cheng Yi-Jie Kuo Chiehfeng Chen Yi-No Kang |
author_facet | Shih-Hao Cheng Yi-Jie Kuo Chiehfeng Chen Yi-No Kang |
author_sort | Shih-Hao Cheng |
collection | DOAJ |
description | <h4>Background</h4>Giving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion surgery of thoracic and lumbar spine.<h4>Methods</h4>We searched EMBASE and PubMed for randomized clinical trials (RCTs) and prospective comparative studies using teriparatide or bisphosphonate in peri-operative spinal fusion surgery. Our synthesized data of fusion rate, Oswestry disability index (ODI), and adverse event in contrast-based network meta-analysis. Pooled results were presented in risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI).<h4>Results</h4>Our search hit eight RCTs and three prospective studies with 676 patients receiving spinal surgery. Pooled result showed that teriparatide+Denosumab leads to significantly higher fusion rate than placebo (RR, 2.84; 95% CI: 1.22 to 6.60) and bisphosphonate (RR, 2.59; 95% CI: 1.13 to 5.96). We did not observe significant finding among placebo, teriparatide, and bisphosphonate in the two network models.<h4>Conclusion</h4>This is the first network meta-analysis providing an overview of the use of teriparatide and bisphosphonate for spinal fusion surgery. Teriparatide treatments are worth to be consider for spinal fusion surgery. |
first_indexed | 2024-12-17T21:49:43Z |
format | Article |
id | doaj.art-23d53787ad5344b98706cd7dee1e56cd |
institution | Directory Open Access Journal |
issn | 1932-6203 |
language | English |
last_indexed | 2024-12-17T21:49:43Z |
publishDate | 2020-01-01 |
publisher | Public Library of Science (PLoS) |
record_format | Article |
series | PLoS ONE |
spelling | doaj.art-23d53787ad5344b98706cd7dee1e56cd2022-12-21T21:31:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01159e023756610.1371/journal.pone.0237566Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis.Shih-Hao ChengYi-Jie KuoChiehfeng ChenYi-No Kang<h4>Background</h4>Giving patients anti-osteoporotic agents peri-operatively is a well-accepted strategy to increase fusion rate and prevent complications. The purpose of this study was to investigate effectiveness of teriparatide and bisphosphonate on fusion surgery of thoracic and lumbar spine.<h4>Methods</h4>We searched EMBASE and PubMed for randomized clinical trials (RCTs) and prospective comparative studies using teriparatide or bisphosphonate in peri-operative spinal fusion surgery. Our synthesized data of fusion rate, Oswestry disability index (ODI), and adverse event in contrast-based network meta-analysis. Pooled results were presented in risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI).<h4>Results</h4>Our search hit eight RCTs and three prospective studies with 676 patients receiving spinal surgery. Pooled result showed that teriparatide+Denosumab leads to significantly higher fusion rate than placebo (RR, 2.84; 95% CI: 1.22 to 6.60) and bisphosphonate (RR, 2.59; 95% CI: 1.13 to 5.96). We did not observe significant finding among placebo, teriparatide, and bisphosphonate in the two network models.<h4>Conclusion</h4>This is the first network meta-analysis providing an overview of the use of teriparatide and bisphosphonate for spinal fusion surgery. Teriparatide treatments are worth to be consider for spinal fusion surgery.https://doi.org/10.1371/journal.pone.0237566 |
spellingShingle | Shih-Hao Cheng Yi-Jie Kuo Chiehfeng Chen Yi-No Kang Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis. PLoS ONE |
title | Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis. |
title_full | Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis. |
title_fullStr | Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis. |
title_full_unstemmed | Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis. |
title_short | Effects of teriparatide and bisphosphonate on spinal fusion procedure: A systematic review and network meta-analysis. |
title_sort | effects of teriparatide and bisphosphonate on spinal fusion procedure a systematic review and network meta analysis |
url | https://doi.org/10.1371/journal.pone.0237566 |
work_keys_str_mv | AT shihhaocheng effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis AT yijiekuo effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis AT chiehfengchen effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis AT yinokang effectsofteriparatideandbisphosphonateonspinalfusionprocedureasystematicreviewandnetworkmetaanalysis |